Table 3.
Clinical trials evaluating ofatumumab in indolent lymphomas.
| Study | Number of patients (histotypes) | Population | Treatment schedule | ORR% (CR) | PFS (months) |
|---|---|---|---|---|---|
| Hagenbeek et al. [2008] | 40 (FL) | Rel/Ref | Ofatumumab (300 to 1000 mg x4, q7) | 43 | 8.8 |
| Czuczman et al. [2012a] | 116 (FL) | Rituximab-Ref | Ofatumumab (500 or 1000 mg x8, q7) | 13 versus 10 | 5.8 |
| Czuczman et al. [2012b] | 58 (FL) | 1st-line | Ofatumumab (500 versus 1000 mg + CHOP x6, q21) | 90 (24) versus 100 (38) |
FL, follicular lymphoma; Rel/Ref, relapsed/refractory; ORR, overall response rate; CR, complete remission; PFS, progression-free survival